This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SUNDAY, Sept. 22, 2024 -- It's that time of year when respiratory viruses start to circulate widely, but how can you tell the difference between the symptoms of a cold, the flu and COVID?Dr. William Brian Glenn, from Hackensack Meridian Medical.
Andrew D Huber, Taosheng Chen eLife 2024, 13 :e101446. [link] The article presents the discussion on interaction of covalent inhibitors GW9662 and T0070907 with the peroxisome proliferator-activated receptor gamma (PPARγ), revealing new insights into how these compounds influence receptor activity. Topics include the role of PPARγ in regulating fatty tissue and glucose levels; and the effects of covalent inhibitors on PPARγ's ligand-binding site and its interaction with co-activators and co-repr
By Steven J. Gonzalez & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — On August 22, 2024, FDA hosted a webinar to provide further guidance on the regulatory requirements it intends to apply to Laboratory Developed Test (LDT) developers in Stage 1 of the phaseout policy of the LDT Final Rule – during which FDA has said laboratories developing LDTs will need to comply with Medical Device Reporting (MDR) (21 CFR Part 803), Corrections and Removals (21 CFR Part 806), and Complaint
In Part 1 of this series, we explored the basics of state management in Lightning Web Components (LWC), focusing on local state management within individual components. If you haven’t read it yet, I recommend starting with Part 1 to grasp the foundational concepts. In this second part, we’ll dive into more advanced territory: shared and global state management.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Today, we’re launching Issue 04 with this essay about the future of fertility and in vitro oogenesis — a technology that could soon be used to convert human skin cells into eggs or sperm — by one of its foremost developers. Thanks for reading. In March 2023, a research team at Osaka University announced an extraordinary achievement : the production of viable eggs using cells taken from male mice.
In an increasingly digital world, security is a top priority for organizations handling sensitive data, especially on platforms like Salesforce. As cyber threats become more sophisticated, traditional security measures may no longer be enough to protect against emerging risks. Enter Artificial Intelligence (AI), which offers a game-changing approach to Salesforce security by detecting anomalies, identifying potential threats, and automating responses.
In an increasingly digital world, security is a top priority for organizations handling sensitive data, especially on platforms like Salesforce. As cyber threats become more sophisticated, traditional security measures may no longer be enough to protect against emerging risks. Enter Artificial Intelligence (AI), which offers a game-changing approach to Salesforce security by detecting anomalies, identifying potential threats, and automating responses.
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content